Calcium Signaling Dysregulation In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
Calcium (Ca²⁺) Signaling Dysregulation represents one of the earliest and most consistent pathological features across neurodegenerative diseases. Calcium serves as a universal second messenger controlling neuronal excitability, synaptic transmission, gene expression, metabolism, and cell survival. Disruption of calcium homeostasis initiates cascades that lead to synaptic failure, mitochondrial dysfunction, protein aggregation, and ultimately neuronal death in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and other disorders.
Neurons regulate Ca²⁺ through multiple channels:
| Channel Type | Function | Location |
|---|---|---|
| Voltage-gated Ca²⁺ channels (VGCC) | Depolarization-induced influx | Somatodendritic, synaptic terminals |
| NMDA receptors | Glutamate-evoked Ca²⁺ entry | Postsynaptic densities |
| AMPA receptors | Fast excitatory transmission | Postsynaptic |
| Metabotropic glutamate receptors (mGluR) | G-protein coupled Ca²⁺ release | Dendrites, soma |
| Voltage-gated sodium channels | Action potential generation | Axon initial segment |
| Store-operated channels (ORAI, TRPC) | Refilling internal stores | Plasma membrane |
| Ionotropic serotonin receptors | Neuromodulatory Ca²⁺ entry | Varies by region |
Early Events
Pathological Cascade
Aβ oligomers → Membrane insertion → Ca²⁺ influx
↓
NMDA/VDCC activation → Ca²⁺/calmodulin activation
↓
Calcineurin activation → Dephosphorylation of tau
↓
GSK3β/CDK5 activation → Tau hyperphosphorylation
↓
Synaptic failure and neuronal death
Key Mechanisms
Dopaminergic Neuron Vulnerability
α-Synuclein Effects
PD Risk Genes
Excitotoxicity
Mutant SOD1 Effects
Calmodulin (CaM) is the primary calcium sensor:
Calcium/calmodulin-dependent protein kinases:
Increased [Ca²⁺]i → Calcineurin activation
↓
NFAT dephosphorylation
↓
Nuclear translocation
↓
Gene transcription (synaptic proteins, cytokines)
| Drug/Compound | Target | Status |
|---|---|---|
| Amlodipine | L-type (Cav1.2) | Clinical trials for AD |
| Nimodipine | L-type | Investigational |
| Memantine | NMDA receptor | FDA approved for AD |
| Riluzole | VGCC, glutamate release | FDA approved for ALS |
| Ziconotide | N-type (Cav2.2) | Pain management |
The study of Calcium Signaling Dysregulation In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Berridge, M.J. (2010). Calcium signalling and Alzheimer's disease. Neurobiol. Aging, 31(5): 766-773.
Popugaeva, E., et al. (2017). Restoring calcium homeostasis to treat Alzheimer's disease: A future perspective. Neurodegener. Dis., 17(4-5): 173-181.
Surmeier, D.J., et al. (2017). Calcium and Parkinson's disease. Biochem. Biophys. Res. Commun., 483(4): 1013-1019.
Chan, C.S., et al. (2010). L-type Ca²⁺ channel antagonists reduce the vulnerability of substantia nigra dopamine neurons. J. Neurophysiol., 103(2): 1069-1080.
Jaiswal, M.K. (2017). Calcium, mitochondria, and the pathogenesis of ALS. J. Neurochem., 142(2): 194-203.
Bezprozvanny, I. (2009). Calcium signaling and neurodegenerative diseases. Trends Mol. Med., 15(3): 89-100.
Mattson, M.P. (2007). Calcium and neurodegeneration. Aging Cell, 6(3): 337-350.
Khachaturian, Z.S. (1987). Hypothesis on the regulation of intracellular calcium homeostasis as a biological marker for age-related brain dysfunction and Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry, 11(2-3): 283-286.
LaFerla, F.M. (2002). Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease. Nat. Rev. Neurosci., 3(11): 862-872.
Tong, B.C., et al. (2021). Calcium signaling in the development and treatment of neurodegenerative diseases. Cell Calcium, 97: 102415.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 10 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 50% |
Overall Confidence: 31%